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Abstract
Aims Progressive left ventricular (LV) remodelling with cardiac myocyte hypertrophy, myocardial fibrosis, and endothelial
dysfunction plays a key role in the onset and progression of heart failure with preserved ejection fraction. The Beta3-LVH
trial will test the hypothesis that the β3 adrenergic receptor agonist mirabegron will improve LV hypertrophy and diastolic
function in patients with hypertensive structural heart disease at high risk for developing heart failure with preserved ejec-
tion fraction.
Methods and results Beta3-LVH is a randomized, placebo-controlled, double-blind, two-armed, multicentre, European, par-
allel group study. A total of 296 patients will be randomly assigned to receive either mirabegron 50 mg daily or placebo over
12 months. The main inclusion criterion is the presence of LV hypertrophy, that is, increased LV mass index (LVMi) or increased
wall thickening by echocardiography. The co-primary endpoints are a change in LVMi by cardiac magnetic resonance imaging
and a change in LV diastolic function (assessed by the E/e0 ratio). Secondary endpoints include mirabegron’s effects on cardiac
fibrosis, left atrial volume index, maximal exercise capacity, and laboratory markers. Two substudies will evaluate mirabegron’s
effect on endothelial function by pulse amplitude tonometry and brown fat activity by positron emission tomography using
17F-fluorodeoxyglucose. Morbidity and mortality as well as safety aspects will also be assessed.
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Introduction
Heart failure (HF) represents a major and growing public
health burden, affecting 2–3% of adults in developed coun-
tries.1 It affects predominantly the elderly, with over 80% of
HF hospitalizations occurring in persons over 65 years of
age.2 Up to half of HF cases occur in the setting of preserved
left ventricular (LV) ejection fraction (HFpEF), a proportion
that will continue to rise at an alarming rate of around 1%
per year in part because of the progressive ageing of the pop-
ulation.2–5 Besides healthcare expenditure, HFpEF puts a
heavy burden on the quality of life of (mostly elderly) pa-
tients, with a loss of autonomy and the discomfort of re-
peated hospitalizations. Therefore, HFpEF is a chronic,
costly, debilitating disease.
Furthermore, symptomatic HF is only the surface of the
emerging HF epidemic. The ageing population along with in-
creasing rates of hypertension, diabetes, and obesity creates
a growing pool of individuals at particularly high risk for HF
development. The American College of Cardiology/American
Heart Association HF staging model emphasizes identification
of these asymptomatic at risk patients without (Stage A) or
with (Stage B) evidence of cardiac remodelling to facilitate
preventative action prior to progression to symptomatic HF
(Stage C).6 Thus, the detection and counteraction of asymp-
tomatic at risk patients may be important to reduce the inci-
dence of clinical HFpEF.
Despite the growing incidence of HFpEF over the last
15 years, there are currently no proven effective therapies.
Indeed, despite encouraging results from some ALDOsterone
receptor blockade in Diastolic Heart Failure (ALDO-DHF)7 but
not all Nitrate’s Effect on Activity Tolerance in Heart Failure
with Preserved Ejection Fraction (NEAT-HFpEF)8 Phase II tri-
als, all outcome Phase III trials have been neutral so far
[Perindopril in Elderly People with Chronic Heart Failure
(PEP-CHF), Candesartan in Heart failure: Assessment of Re-
duction in Mortality and morbidity (CHARM)-Preserved study,
Irbesartan in Heart Failure with Preserved Ejection Fraction (I-
PRESERVE) and Treatment of Preserved Cardiac Function
Heart Failure with an Aldosterone Antagonist trial
(TOPCAT)].9–12 The prEserveD left ventricular ejectIon frac-
tion chronic heart Failure with ivabradine studY (EDIFY) trial
included 179 patients in New York Heart Association (NYHA)
Classes II and III, in sinus rhythm, with heart rate of ≥70 b.
p.m., and ivabradine (or placebo) was titrated to 7.5 mg b.i.
d. No evidence of improvement was found in any of the three
co-primary endpoints (E/e0 ratio, 6 min walking test and
N-terminal pro brain natriuretic peptide (NT-proBNP).13 More
recently, in the Prospective comparison of ARNI with ARB on
Management Of heart failUre with preserved ejectioN frac-
Tion (PARAMOUNT) trial, the new drug LCZ696 (combining
valsartan and sacubitril, a neprilysin inhibitor) was tested
against valsartan alone in patients with HF and LV ejection
fraction (LVEF) ≥45% (80% of whom were in NYHA Class II);
the primary endpoint was a change in NT-proBNP, a marker
of LV wall stress, from baseline to 12 weeks.14 The results
showed a significant lowering of NT-proBNP at 12 weeks in
the LCZ696 group vs. valsartan alone, but it was not sustained
at 36 weeks. Another trial, SOluble guanylate Cyclase stimula-
toR in heArT failurE patientS with PRESERVED EF (SOCRATES-
PRESERVED) study, tested the soluble guanylyl cyclase, stimu-
lator, vericiguat, against placebo in symptomatic (NYHA Clas-
ses II–IV) patients with LVEF ≥45% and left atrial (LA)
enlargement, who experienced a recent acute decompensa-
tion event. Despite lack of an effect on NT-proBNP and LA
volume, the patient-reported symptoms and functional limi-
tations, assessed by the Kansas City Cardiomyopathy Ques-
tionnaire score, were improved with the higher two doses
of vericiguat compared with placebo.15,16
Notably, both PARAMOUNT and SOCRATES-PRESERVED
tested drugs known to increase intracellular (including car-
diac myocyte) cyclic guanosine monophosphate (cGMP).
Despite mitigated results in these two trials, their partial effi-
cacy raises the interest for therapeutic strategies acting on
the same pathway, albeit through different pharmacody-
namic mechanisms. Accordingly, the Beta3-LVH trial will
provide a proof of concept in humans for the clinical efficacy
of β3 adrenergic receptor (β3AR) activation to attenuate/
prevent cardiac remodelling. β3AR is expressed in several hu-
man tissues, including bladder muscle, and also cardiac and
vascular tissues.17–19 β3AR couples to the nitric oxide (NO)/
cGMP pathway, resulting in coronary vasodilatation, and
raises cGMP in human myocardium, with a resulting effect
on cardiac myocytes that is antipathetic to classical β1–2AR
positive inotropic effects.19,20 In preclinical studies, activation
of β3AR decreases myocardial hypertrophy and fibrosis in
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response to neurohormonal or haemodynamic stresses,
without compromising LV function.21,22 As ample evidence
now points to the adverse effects of sustained activation of
β1–2AR, leading to receptor desensitization/internalization,
loss of contractile/frequency reserve, adverse remodelling,
calcium overload, and myocyte loss, we reasoned that activa-
tion of the functionally antipathetic β3AR would protect
against such deleterious effects of chronic adrenergic stimu-
lation. The trial will test the effect of mirabegron, a β3AR-se-
lective agonist that was developed and marketed for clinical
use in overactive bladder disease, on LV mass and diastolic
function.23 Therefore, this trial will examine the ‘drug
repurposing’ of mirabegron to HFpEF, a highly prevalent dis-
ease affecting mostly elderly patients.
Methods
Study objectives
The primary objective of this trial is to determine whether the
β3AR-specific agonist mirabegron is superior to placebo in de-
creasing LV mass and/or improving diastolic function in pa-
tients with LV structural remodelling with or without
symptoms of HF (NYHA Class ≤II).
Besides the primary effect of mirabegron on LV hypertro-
phy, its effect on other indicators for HFpEF, that is, cardiac
fibrosis, LA volume index, maximal exercise capacity, and lab-
oratory markers, will be analysed.
Study design
Beta3-LVH is a two-armed, prospective, randomized, placebo-
controlled, double-blind, multicentric European Phase IIb
clinical trial. Participating trial centres will screen all consecu-
tive outpatients and inpatients for entry inclusion and exclu-
sion criteria. Patients who fulfil study entry criteria will be
randomized to receive either mirabegron or placebo (ran-
domization ratio 1:1).
Over a 36 month period, we plan to recruit a total of 296
patients from 10 clinical trial sites in eight European coun-
tries. A study flow chart is shown in Figure 1.
Inclusion and exclusion criteria
The study inclusion and exclusion criteria are listed in Table 1.
The main inclusion criteria are as follows: presence of LVH by
echocardiography, that is, increased LV mass index by echo-
cardiography (≥95 g/m2 for female; ≥115 g/m2 for male) or
end-diastolic wall thickness ≥13 mm in at least one wall seg-
ment, in the absence of genetic hypertrophic cardiomyopa-
thy and significant valvular disease.2,27
It is anticipated that most of these patients will have
systemic hypertension; if so, they will be required to be
on stable therapy according to current guideline algo-
rithms (including stable medication for at least 4 weeks
before inclusion) and a well-controlled hypertension. This
patient population is known to be most likely to develop
progressive hypertensive cardiac remodelling and/or
HFpEF.28
Figure 1 Synopsis of the Beta3-LVH trial.
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Table 1 Inclusion and exclusion criteria
Inclusion criteria
Age between 18 and 90 years
Morphological signs of structural cardiac remodelling by echocardiography, that is, increased LV mass index (95 g/m2 or higher for
female; 115 g/m2 or higher for male subjects or end-diastolic wall thickness ≥13 mm in at least one wall segment1
Written informed consent: for subjects unable to read and/or write, oral informed consent observed by an independent witness is
acceptable if the subject has fully understood oral information given by the investigator. The witness should sign the consent form on
behalf of the subject.
Note: patients are allowed to take a β1–2-blocker, other than the drugs listed in the exclusion criteria
Exclusion criteria
Uncontrolled hypertension with systolic BP ≥160 mmHg and/or diastolic BP ≥100 mmHg (confirmed at three consecutive office
measurements in sitting position); if so, the patient may be re-screened after optimization of anti-hypertensive treatment.
Hypertensive patients not under stable therapy according to current guideline algorithm (including stable medication for at least
4 weeks before inclusion)24
Documented ischaemic cardiac disease is as follows:
• current angina pectoris,
• ischaemia on stress test,
• untreated coronary stenosis >50%,
• history of AMI,
• CABG (<3 months prior to screening), or
• PTCA less than 3 months prior to screening.
Patients with uncontrolled recurrent persistent and permanent AF according to AHA/ACC/ESC guidelines25 (with a HR >100 per minute,
RACE II26). If AF with HR >100 per minute, the patient may be re-screened after treatment for rate control.
History of hospitalization for overt heart failure within last 12 months
Patients after heart transplantation
History of high-degree impulse conduction blocks (greater than second-degree AV block Type 2)
Hypertrophic or dilated cardiomyopathy
EF <50%, regardless of symptoms
Significant valvulopathy (less than 1 cm2 aortic valve area or significant mitral valve insufficiency at Doppler echocardiography) and/or
previous valvular surgery
Congenital valvulopathies
Patients with a known history of QT prolongation (QT >450 ms) or patients with documented QT prolongation (QT >450 ms) while
taking medicinal products known to prolong the QT interval
NYHA Class >II
BMI ≥ 40 kg/m2
Hyperthyroidism/hypothyroidism
Known other cause (i.e. COPD) of respiratory dysfunction. Patients under positive pressure (CPAP) treatment for sleep apnoea syndrome
may be included, provided they have been efficiently controlled under regular treatment for at least 1 year before inclusion in the study
Moderate renal impairment defined as eGFR <30 mL/min
Abnormal liver function tests (AST or ALT >2× upper normal limit or patients with known hepatic impairment defined as Child–Pugh
Class B or higher)
Type I diabetes, complicated Type II diabetes (i.e. with documented coronary macroangiopathy, confer (cfr) exclusion criterion 1, or
documented other vascular complication)
Patients with anaemia (male: Hb <13.0 g/L; female: Hb <12.0 g/L)
Patients with bladder outlet obstruction
Patients using antimuscarinic cholinergic drugs for treatment of OBD
Current use of digitalis, bupranolol, propranolol, and nebivolol (known to interfere with β3AR signalling)
Patients continuously treated with sildenafil or other PDE5 inhibitors
Current use of antifungal azole derivatives (fluconazole, itraconazole, miconazole, posaconazole, and voriconazole) (known inhibitors
of CYP3A4, the main metabolizer of mirabegron)
Current treatment with mirabegron or indication for future treatment with mirabegron due to other indications
Contraindication for MRI (e.g. defibrillator, ferromagnetic devices, or severe claustrophobia)
Pregnant or nursing women
Participation in any other interventional trial: patients unable to give informed consent (people under legal guardianship)
Women of child-bearing potential without highly effective contraceptive measures
Contraindication to mirabegron (e.g. hypersensitivity)
β3AR, β3 adrenergic receptor; AF, atrial fibrillation; AHA/ACC/ESC, American College of Cardiology/American Heart Association/European
Society of Cardiology; ALT, alanine transaminase; AMI, acute myocardial infarction; AST, aspartate transaminase; AV, atrioventricular;
BP, blood pressure; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; CPAP, continuous positive airway
pressure; EF, ejection fraction; eGFR, estimated glomerular filtration rate; Hb, haemoglobin; HR, heart rate; LV, left ventricular; MRI, mag-
netic resonance imaging; NYHA, New York Heart Association; OBD, overactive bladder disease; PTCA, percutaneous transluminal coronary
angioplasty; RACE II, Rate Control Efficacy in Permanent Atrial Fibrillation.
In case of discrepancy between ambulatory and in office blood pressure, the office assessment prevails. GFR (mL/min/
1.73 m2) = 175 × (Scr)
1.154 × (age)0.203 × (0.742 if female) × (1.212 if African American), from http://nkdep.nih.gov/lab-evaluation/
gfr/estimating.shtml#mdrd-study-equation. In case of current treatment with one of the excluded drugs, patients can be re-screened af-
ter a washout period of three half-lives.
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Duration of the trial
Each patient will be treated with placebo/mirabegron over a
period of 12 months. Thus, trial participation encompasses
52 weeks per patient. There will be no long-time follow-up.
A safety phone call will be performed 4 weeks after a patient
has stopped taking study medication.
Study medication
Mirabegron will be tested against placebo in patients receiv-
ing conventional background therapy (e.g. for hypertension),
which will be prescribed at the discretion of the treating phy-
sician. Bupranolol, propranolol, or nebivolol (known to inter-
fere with β3AR signalling) are not allowed and listed as
exclusion criterion. Other medications not allowed in the trial
are listed in Table 1. Administration of the first dose of the
study drug is part of the randomization procedure and will
be supervised by the local investigator. There is no
up-titration planned. The study drug will be labelled as




We define two equally ranked, primary endpoints, in order to
assess both structural and functional aspects of LV remodel-
ling (Table 2):
• Change in LV mass index (in g/m2, defined as LV mass
divided by body surface) measured at baseline and 6
and 12 months after randomization. Cardiac magnetic
resonance (CMR) is performed locally according to a
standardized protocol, and LV mass index will be
measured in the central CMR core lab. Regression of LV
hypertrophy, which is reflected by reduction in the LV
mass index, is known to be associated with favourable
clinical outcomes.30
• Change in LV diastolic function, assessed as the ratio of
peak early transmitral ventricular filling velocity to early
diastolic tissue Doppler velocity (E/e0) measured at
baseline and 6 and 12 months after randomization. This
parameter will be assessed by echocardiography, per-
formed locally according to a standardized protocol, and
will be measured in the central echo core lab. E/e0 is an
established indicator of diastolic function and has been
shown to reliably detect changes in functional perfor-
mance.31–35 In addition, change in E/e0 has been shown
to be associated with the change in self-reported physical
functioning.36
Furthermore, Beta3-LVH will investigate several secondary




All participants will undergo a CMR scan performed on the
same 1.5T or 3T magnetic resonance system in each centre.
Given the variation of magnetic resonance systems between
centres, acquisitions are performed with sequences preferred
by each centre, subject to the quality checks by the central
core lab to assure that the images are fit for purpose.
Typically, after standardized planning, CMR will be ac-
quired with an electrocardiogram-gated, breath-hold, two-
dimensional, steady-state free precession cine sequence as
previously described.37 Long-axis views and short-axis cine
stack will be used for the calculation of the LV mass and
function.
Table 2 Primary, secondary, and safety endpoints
Primary endpoints
• Change in LV mass index measured at baseline and 6 and 12 months after randomization
• Change in diastolic function, assessed as the ratio of peak early transmitral ventricular filling velocity to early diastolic tissue Doppler velocity
(E/e0) measured at baseline and 6 and 12 months after randomization
Secondary endpoints
• CMR endpoints (all measured in the central CMR core lab)
○ Cardiac fibrosis at baseline and at 12 months
○ LAVI at baseline and at 12 months
• Laboratory parameters at baseline and at 3, 6, and 12 months
○ serum biomarkers (Galectin3, GDF15, NT-proBNP, and hsTnT)
○ metabolic parameters (fasting glucose, modified HOMA test, HbA1c, and serum lipids)
• Maximal exercise capacity (peak VO2) at baseline and 12 months
Safety endpoints
• Incidence, severity, and frequency of adverse and serious adverse events
• Mortality
CMR, cardiac magnetic resonance; HbA1c, glycated haemoglobin; HOMA, homeostatic model assessment; LAVI, left atrial volume index;
LV, left ventricular; NT-proBNP, N-terminal pro brain natriuretic peptide.
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Pre-contrast T1 mapping images will be acquired at the
basal, mid-cavity, and apical levels. A bolus of gadolinium-
based contrast agent (0.15 mmol/kg) and a 10 mL saline flush
will be administered via a cannula in the patient’s arm. Post-
contrast T1 measurements, at the exact same three short-axis
cuts as the pre-contrast T1 maps, will follow approximately 5,
15, and 30 min after injection of contrast, using an appropri-
ate post-contrast T1 mapping sequence.38
Late gadolinium enhancement images are acquired using
the clinical sequences of choice by each centre, subject to
suitability checks by the central core lab. For quantification
of extracellular volume,39 blood sampling for haematocrit will
be obtained on the same day as the CMR scan.
All the exams will be analysed (in a blinded fashion) by
the CMR core lab. Reproducibility will be investigated and
reported.
Echocardiography
Two-dimensional and M-mode images will be acquired in ac-
cordance with current American Society of Echocardiography
guidelines.40 Participating site sonographers will perform ade-
quate echo examinations on the basis of the echo manual,
followed by submission of a certification echo. Echo Core Lab
will assess test echocardiograms for appropriateness and com-
pleteness of imaging quality according to the study echo
manual, including optimal image quality. Echocardiograms at
randomization, 6 and 12 months, will be read centrally by
the blinded academic echocardiography core lab for analysis
of the primary, secondary, and exploratory echo parameters
according to a pre-specified analysis plan. Conventional analy-
ses including two-dimensional Doppler and tissue Doppler will
be performed by core lab sonographers blinded to clinical in-
formation and treatment assignment using an offline
vendor-independent platform (Tomtec, Munich, Germany).
Cardiopulmonary exercise testing
A reference laboratory will act as the blinded core lab for all
aspects related to cardiopulmonary exercise testing. A final
standard operating procedure for cardiopulmonary exercise
testing is issued by the reference laboratory. Aerobic capacity
(peak VO2) testing will be performed on bicycle according to
a ramp test protocol (10 W/min) after an initial work rate at
20 W. All tests will be symptom limited, with strong encour-
agement to achieve a respiratory exchange ratio that is
>1.10. Criteria for discontinuation of the exercise test are
defined as recommended by the European Society of Cardiol-
ogy.41 A standard 12-lead electrocardiogram will be moni-
tored continuously for heart rate, ST-segment changes, and
arrhythmias. Blood pressure will be recorded at rest and then
every 2 min. Ventilatory exchange (VE), oxygen uptake (VO2),
and other cardiopulmonary variables such as VE/VCO2 slope
will be acquired by averaging breath-by-breath measure-
ments over 10 s intervals. Peak heart rate and workload will
be recorded immediately upon the end of exercise. Peak
VO2 is defined as the maximum value of the last three 10 s
averages during exercise, and anaerobic threshold will be de-
tected using the V-slope method.42 Chronotropic reserve will
be also recorded. VO2 assessments will be performed at in-
clusion and Month 12.
Biometric aspects (see the Supporting
information for extended description)
Randomization
Randomization of patients between active drug and placebo
is performed centrally via a secure web-based tool using a
modified minimization procedure with stochastic component
according to Pocock in a 1:1 proportion.43
Statistical description of the trial hypothesis
This trial aims to demonstrate that mirabegron as add-on to
standard treatment compared with standard treatment alone
improves at least one of the two primary endpoints over
12 months.
The Hochberg method will be used to adjust for endpoint
multiplicity.44 If both P-values are below 0.05, we will claim
efficacy in both primary endpoints; if otherwise the smallest
P-value is below 0.025, we will claim efficacy in the respective
primary endpoint. This procedure controls the family-wise
error rate in the strong sense at a two-sided significance
level of 5%.
Planned methods for analysis
The full analysis set (also called modified intention-to-treat
population) will include all randomized patients with valid in-
formed consent and at least one valid measurement of the
primary endpoints (baseline and 6 or 12 months). A per-
protocol set will also analyse all patients belonging to the in-
tention to treat without major violations of the study
protocol.
For primary and secondary endpoints, mean changes from
baseline meanwill be analysed using a repeatedmeasurement
linear mixedmodel without intercept containing the fixed, cat-
egorical effects of visit (baseline and 6 and 12 months), treat-
ment (active drug/placebo), treatment by visit interaction,
atrial fibrillation (yes/no), diabetes mellitus (yes/no), and a
patient-specific, visit random effect (three-dimensional nor-
mal with a general unstructured variance–covariance matrix).
Sensitivity analyses (specified in the statistical analysis
plan) will include (i) the earlier model restricted to the per
protocol population and (ii) analysis of covariance with base-
line values as covariates and randomization group as factor in
all randomized patients with baseline and 12 months mea-
surements and with imputation of missing values by last in-
formation carried forward.
Additional baseline sources of variability will be explored
during the blinded review of the data, for example, age,
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gender, and NYHA class, and included in explorative multivar-
iate analyses as appropriate. Exploratory subgroup analyses
will include use of a beta-blocker in the standard treatment
(yes/no); this is to test the hypothesis that differential regula-
tion of the expression and coupling of the β3 receptors may
occur under β1AR blockade.
45
All CMR and echo secondary endpoints as well as peak VO2
will be analysed along the same lines as the primary end-
points. All measurements will be performed centrally in cen-
tral core labs (cardiac magnetic resonance imaging and
echocardiography), and reproducibility will be investigated
and reported. Adverse and serious adverse events will be
compared by χ2 tests. Odds ratios with 95% confidence inter-
vals will be provided. All analyses will be pre-specified in a de-
tailed statistical analysis plan, which will be finalized before
unblinding the data.
Sample size
We investigate two equally ranked, primary endpoints. We
conservatively plan sample sizes for a significance level of
2.5%. We base our sample size calculation on the parameter
assessing diastolic function, E/e0, because reliable and consis-
tent planning data for this parameter are available in the lit-
erature.7,36,46 Typically, E/e0 decreases during follow-up in
treated patients, while it increases in control patients, leading
to mean differences of the baseline-to-follow-up changes of
up to 2 between control and treatment group, with a typical
baseline mean of about 12.
In our trial, we aim to detect a difference of 1.2
between active drug and placebo group. This difference
roughly corresponds to 5 points on the SF-36 physical func-
tion scale,36 thus indicating a moderate but patient-
relevant difference. Based on the raw data of the ALDO-
DHF7 and Exercise training in Diastolic Heart Failure (Ex-
DHF)-Pilot36 trials mentioned earlier, which were available
for additional analysis, we assume a standard deviation of
3. This is in line with the sample size assumptions of the
DenervatIon of the renAl Sympathetic nerves in hearT fail-
ure with nOrmal Lv Ejection fraction (DIASTOLE) trial.47
With these assumptions, a total of 272 patients have to
be analysed to achieve a power of 85% at a significance
level of 2.5% using a two-sided t-test (NQuery Advisor®
7.0).
Because there are no data on LVMI in our specific target
population, we cannot fully specify a planning scenario.
However, with 272 patients, an effect size in the magnitude
of 0.4 is detectable with a power of at least 85% at a
significance level of 2.5%. In previous trials such as ALDO-
DHF7 and ex-DFH pilot,36 the drop-out rate was low
(ALDO-DHF 5% in 12 months, ex-DHF-Pilot 3% in 6 months,
Kosmala et al. 1% in 6 months46). Thus, we expect a drop-
out rate not exceeding 8%. Taking this into account, 296 pa-
tients will be randomized.
The Beta3-LVH is a Phase IIb trial and investigates end-
points related to cardiac remodelling. The trial does not ad-
dress hard clinical endpoints and is not designed nor
powered to detect differences in long-term clinical outcome.
However, clinical events are collected (such as death, cardio-
vascular death, HF hospitalizations, and new-onset heart
failure).
Substudies
Two substudies will also assess the effect of mirabegron on
endothelial function by pulse amplitude tonometry,
coupled to measurements of nitrosylated haemoglobin and
brown fat activity by positron emission tomography–
computed tomography using 17F-fluorodeoxyglucose. For
each project, a separate protocol is provided (Supporting
Information).
Ethics
The investigation conforms with the principles outlined in the
Declaration of Helsinki (Br Med J 1964; ii: 177). European
(Voluntary Harmonization Procedure), national, and locally
appointed ethics committees have approved the research
protocol, and informed consent will have been obtained from
all the study subjects.
Study organization
The principal investigator, the study coordinator, and the Clin-
ical Trial Center Leipzig are responsible for all aspects of the
study protocol and amendments. The Steering Committee
guarantees scientific oversight and consulting in all study-
related aspects. A Data Safety and Monitoring Board
operates independently of the other study committees and
of the sponsor. The Data Safety and Monitoring Board will re-
view the progress of the trial and, under blinded conditions,
control the safety of the patients enrolled in Beta3-LVH.
Names and affiliations of all participants involved in Beta3-
LVH are listed in the Appendix.
Discussion
A major contributor to HFpEF is myocardial remodelling, for
example, hypertrophy and fibrosis, as well as cellular
functional/structural modifications leading to impairment in
functional properties (including relaxation) and LV distensibil-
ity. Unfortunately, despite the growing incidence of HFpEF
over the last 15 years, there are currently no evidence-based
treatment strategies that will change its evolution. This puts
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more emphasis on new strategies and targets that may pre-
vent the progression of remodelling towards the development
of LV dysfunction and symptomatic HFpEF. This trial is de-
signed to assess the clinical efficacy of a novel therapeutic
concept: β3AR activation to attenuate/prevent cardiac
remodelling.
Rationale for targeting β3 adrenergic receptor
The underlying mechanistic concept is built on the preclini-
cal demonstration of the coupling of β3AR to the NO
synthase/cGMP pathway, with an expected protection from
myocardial remodelling19,20 (see also Figure 2). The hypoth-
esis was tested in a transgenic mouse model with cardiac
myocyte-specific expression of the human β3AR; these mice
(and their littermate controls) were submitted to a number
of interventions all leading to myocardial stress (i.e. mini-
pump or i.p. infusions of isoproterenol or angiotensin II,
transaortic constriction). The results uniformly showed pro-
tection of the transgenic mice from the development of
pathological remodelling contrary to the wild-type con-
trols.21,22 Importantly, this was not at the expense of LV
function, which remained normal. The β3AR may then be
an attractive target to prevent adverse remodelling in the
face of chronic adrenergic stimulation, all the more because
it is distinctively resistant to homologous desensitization
(rodent and human β3ARs lack consensus sequences for
phosphorylation by βARK or PKA) and retains coupling to
downstream signalling in the pathological heart, as demon-
strated in human diseased myocardium ex vivo.17 Moreover,
contrary to β1–2AR, its expression increases in the diseased
myocardium. On the basis of observations in transgenic
mice, one can assume that this β3AR upregulation is a pro-
tective mechanism in the face of myocardial stress. How-
ever, as the β3AR is typically activated by higher
catecholamine concentrations (than β1/2AR), it is possible
that this protective pathway is not maximally recruited even
in circumstances of pathophysiological adrenergic activation.
This would leave a therapeutic margin for additional activa-
tion by a potent and specific β3AR agonist, such as
mirabegron.
Figure 2 Targets for the therapeutic effect of mirabegron. As β3 adrenergic receptor agonist, mirabegron is expected to activate β3 adrenergic recep-
tors in adipocytes (left), resulting in increased adipocyte ‘browning’, energy expenditure, and peripheral insulin sensitivity; in endothelial cells of the
vasculature (centre; including coronary resistance arteries), thereby increasing endothelium-dependent vasodilatation, myocardial perfusion, and para-
crine nitric oxide-mediated signalling; and in cardiac myocytes (right), resulting in antioxidant and cyclic guanosine monophosphate-mediated protec-
tive effects against remodelling and improved relaxation. Altogether, these effects are expected to prevent myocardial ischaemia and improve diastolic
function.
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Based on older evidence,18 there were concerns that the
therapeutic potential of β3AR agonists would be limited by
cardiodepressive effects, following the demonstration that,
ex vivo, cardiac β3AR stimulation was associated with nega-
tive inotropy in human ventricular samples. However, this
was only observed at high concentrations of agonists that
exceed clinically relevant plasma levels. That administration
of BRL37344, a β3AR agonist, in large animal models of HF
does not translate to decreased cardiac performance
in vivo,48 mitigates these concerns. In addition, administra-
tion of mirabegron in a small group of patients with severe
HFrEF (ejection fraction <40%) resulted in improvement of
LV function in the BEta 3 Agonists Treatment in HF (BEAT-
HF) trial (see the succeeding texts).49
Importantly, β3AR also mediate antioxidant effects
22 that,
unlike previous therapeutic approaches with guanylyl cyclase
stimulators (vericiguat) or PDE5 inhibitors (sildenafil), would
protect the NO/cGMP signalling from oxidative degradation
and preserve its efficacy in remodelling myocardium with
prevailing oxidant stress. This antioxidant effect also contrib-
utes to decrease paracrine pro-fibrotic signalling.22 This anti-
fibrotic effect is likely to prevent further degradation of LV
compliance leading to HFpEF, as fibrosis is a pathogenic com-
ponent of diastolic dysfunction.50 In addition, β3AR was also
shown to attenuate the oxidative inactivation of the Na-K-
ATPase pump in animal models, thereby reducing Na over-
load in the failing heart; this may also contribute to correct
diastolic dysfunction.51 These effects add up with those on
coronary NO release and vasodilatation mediated by β3AR ac-
tivation on coronary microvascular endothelial cells, which
would contribute paracrine effects on LV relaxation and in-
crease coronary perfusion, thereby avoiding further ischae-
mic damage.
Notably, activating β3AR may provide a more regulated
and targeted activation of cGMP downstream pathways
than stimulators or activators of the soluble guanylyl cy-
clase, which need careful dose finding to avoid detrimental
systemic hypotension. Mirabegron was also well tolerated
in combination with β1–2AR-blockers in the BEAT-HF trial,
an association also allowed in the present Beta3-LVH trial;
such combination would not only avoid off-target agonism
at β1–2AR but may even reinforce the effects on down-
stream NO synthase/cGMP signalling.45 In the Beta3-LVH
trial, only unspecific β1–2–3AR-blockers, such as propranolol
or bupranolol, are not allowed, as well as nebivolol which,
aside from specific β1AR blockade, is also endowed with
β3AR agonist activity. Note that commonly used β1–2AR-
blockers previously tested in RCT of HF (e.g. bisoprolol,
metoprolol, and carvedilol) exhibit at least 100-fold less af-
finity for β3AR and so would leave it unaffected.
52 Finally,
one can expect indirect cardiovascular benefits from activa-
tion of β3AR in extracardiac targets, such as beige/brown
fat, with ensuing improvements in peripheral metabolism
and insulin sensitivity, justifying our substudies on
endothelial function, metabolic parameters, and brown
fat activation by fluorodeoxyglucose–positron emission
tomography.
Safety and tolerability of mirabegron in the target
population
Clinical data from the mirabegron clinical studies in overac-
tive bladder disease did not raise major concerns in terms
of safety and tolerability (see the Supporting Information
for more details). In healthy volunteers, mirabegron causes
a dose-dependent increase in heart rate (3–6 h post-dosing)
and in systolic blood pressure (24 h average), which has been
attributed to baroreflex activation secondary to short-term
hypotensive effects. In the clinical trial populations, in aggre-
gate, this translated to an increase of approximately 1 b.p.m.
in heart rate and an increase in systolic blood pressure
of <1 mmHg, which was not associated with increased car-
diovascular complications (European Medicines Agency
mirabegron EPAR report EMA/706651/2012), at least up to
8–12 weeks in the initial Phase II trials. Although safety and
tolerability studies with 1 year treatment duration confirmed
this, post-marketing survey identified an increased risk of
cardiovascular complications in patients with uncontrolled
hypertension (an exclusion criterion in the present trial).23
The-first-in-man randomized trial of a β3AR agonist in
chronic HF (BEAT-HF) was recently conducted in 70 patients
with NYHA Classes II and III HF and LVEF <40% at screening
echocardiography.49 Patients received mirabegron or placebo
for 6 months as add-on to optimized standard therapy. The
primary endpoint of an increase in LVEF after 6 months as
measured by computed tomography was not reached. Explor-
atory analysis indicated that β3AR stimulation by mirabegron
increased LVEF in patients with severe HF. In that study, treat-
ment with mirabegron appeared safe and did not cause pro-
longation of the QT interval in the entire cohort or in the
subgroup with LVEF<40%. The exploratory data indicate that
mirabegron increases contractility in the state of more di-
lated left ventricles, rather than induction of remodelling
with reduced diastolic dimensions. However, LV mass was
not reported.
Conclusions
Heart failure with preserved ejection fraction is a common,
disabling, and costly disease. However, no established
therapeutic strategies exist. Beta3-LVH is the first clinical trial
to assess the effect of mirabegron, a β3 adrenergic receptor
agonist on LV mass and diastolic function in patients with
structural heart disease in order to prevent progression to
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more advanced stages. This trial will provide important infor-
mation on therapeutic strategies in these patients.
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